Laboratory Supplies

The total Ultraviolet Systems market has reached 2 billion US $ worldwide in the whole value-chain, more and more companies enter this market and increase competition, but applications too.Strong increase in selected applications more than 15 percent.

New Study by helmut kaiser consultancy http://www.hkc22.com/ultraviolet.html


Since several years UV Technologies find more and more applications and the markets show strong increase worldwide, in selected applications more than 15 percent. Coming out of the shadow of other technologies UV is more and more viable. Disinfection in Water, Air and Food drives through public awareness, regulations, no by-products, non chemical alternative, inexpensive functions and environmentally friendly. The markets increase in different applications exponential and we expect this development for the next 10 years specialy in water, wastewater, food and air applications but also some new applications. The total market has reached 2 billion US $ worldwide in the whole value-chain, more and more companies enter this market and increase competition, but applications too.

The markets for water disinfection, water purification and securing water quality with other methods is growing worldwide between 8 and 25 percent depending on the sector, branch and country. UV disinfection with nanotechnologies and molecular technologies will change the water treatment markets in the next 10 years dramatically. The costs and prices of water in the future will largely depend on the disinfection necessity and the applied technologies. A special part about nanotechnology and molecular technology is added in the study for the first time. A number of nanotechnologies are already utilised UV disinfection. More applications are to be found in the next years.

Meanwhile the standard of UV systems used on air and surface disinfection, water disinfection and food and beverage disinfection are becoming more stringent, complex and costly. In this study different UV disinfection market segments will be discussed. This includes technology, processes, application, regions, main countries, branches and industries, distributions and value chain, and also customer based strategies.

The market prospect of UV disinfection is promising. With the increasing demand, the total market volume is expected to grow from 2.1 billion US$ in 2006 to 2.3 bn. US$ in 2007 and reach 4.9 bn. US$ up to 2015.

Observed by regions, West Europe and North America have a high starting point, but will have moderate growth rate. Asian countries have the fastest increase. On the one hand, it is due to the booming economy there and the immense scale of infrastruction construction. On the other hand, the warm and humid climate in South/Southeast Asia imposes special requirements on the water disinfection. The proportion of UV disinfection in the water treatment in this region is thus relatively high compared with other places.

In the value chain, the equipment investment takes the largest market share, in 2004 is 48% which amounts 1 billion US$ and it is still increasing during the next years, reaching 2.4 billion US$ up to 2015. for the new construction is the one of the most important momentum for water disinfection industry within ten years. Yet, the highest growth is the the measurement, control and automatic systems installed in the facilities. The total operation in UV disinfection is 0.4 billion US$ in 2006, and will be 0.6 billion US$ in 2007. We expect in 2015 it will reach 1.9 billion US$.

Source: Nanotech-now

Thermo Fisher Scientific Inc. (NYSE: TMO) today announced that it has acquired Priority Solutions International, a leading third-party logistics provider to the pharmaceutical and healthcare industries, following anti-trust clearance. Priority Solutions was previously majority-owned by Arsenal Capital Partners. With revenues of approximately $95 million in 2006, Priority Solutions offers a comprehensive range of services for the delivery of FDA-regulated pharmaceuticals, including shipment of pharmaceutical samples, direct-to-physician patient supplies, and pharmaceutical warehousing and order fulfillment.

Priority Solutions will be integrated into Thermo Fisher's biopharma services business, which includes the packaging and delivery of tightly regulated pharmaceutical samples to patients participating in clinical trials.

"The addition of Priority Solutions will make our biopharma services business an even stronger partner for biotechnology and pharmaceutical customers who are increasingly looking to outsource clinical trials management," said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific. "This acquisition brings tremendous logistics expertise and an infrastructure to our existing outsourcing services that strengthens our ability to deliver pharmaceutical supplies to the right people at the right time - anywhere in the world."

Based in Swedesboro, New Jersey, Priority Solutions' non-asset-based logistics network extends to more than 500 cities worldwide. From order entry to final delivery, Priority Solutions tracks, manages and reports shipment status through call center specialists and a variety of Web-based tools available to both vendors and clients. Throughout the process, each step is fully documented to ensure end-to-end integrity of shipments in the highly regulated pharmaceutical and healthcare industries.

Lee Biosolutions has announced the production and availability of five Human Lactate Dehydrogenase Isoenzymes - LDH-1, LDH-2, LDH-3, LDH-4 and LDH-5 - for purchase at LeeBio.com. Refer to Item No. 355-15 for the most popular LDH Isoenzyme product from the humanheart, LDH-1.

Human lactate dehydrogenase isoenzymes are primarily used by cells in specific tissue. LDH, also known as lactic dehydrogenase, is responsible for converting muscle lactic acid into pyruvic acid, an essential step in producing cellular energy.

When injury occurs, cells containing specific LDH isoenzymes are released in the bloodstream. Analyzing specific LDH isoenzyme ratios helps identify certain patterns in order to aid in the diagnosis ofdisease such as heart attack, lung injury, lung disease, liver or muscle disease, advanced cancers and autoimmune diseases.

According to Lee Biosolutions President Burton Lee, the company keeps close tabs on the clinical research community in an effort to stay ahead of widespread demands for products like Human Lactate Dehydrogenase Isoenzymes.

"Lee Biosolutions has developed a reputation for high-quality biomarker production," said Lee. "We isolate LDH isoenzymes from the humanheart , human red blood cells and the human liver. As a manufacturer of high purity human enzymes, we are able to custom fill orders and we will, likewise, place the protein in the buffer of your choice, if required."

Burton also indicated Lee Biosolutions focuses on providing consistently pure products to the clinical research community. "We continue to expand our product line based on developing trends in the industry," he added.

Lee Biosolutions is a leader in the biomaterials industry, providing quality biomaterial products to clinical labs and researchers around the world, developing tomorrow's cures. The company has provided the proteins used in a number of high profile biomarker studies. For more information or to place an order, contact Lee Biosolutions at 314-968-1091, or visit the company's newly redesigned website, http://www.leebio.com.

EPICENTRE's BACMAX™ DNA Purification Kit enables easy, reliable isolation of exceptionally pure intact BAC DNA without binding columns, resins, or organic extractions. The high-quality BAC DNA is suitable for many applications, including sequencing, fingerprinting, PCR, and preparation of shotgun libraries. The scalable protocol is based on a modified alkaline-lysis procedure that typically yields 0.6 to 25 µg of BAC DNA from a 1.5 to 100 ml culture of a single-copy BAC. Selective precipitation steps and the incorporation of EPICENTRE's RiboShredder™ RNase Blend remove contaminants that degrade DNA and interfere with downstream applications.

Thermo Fisher Scientific, the world leader in serving science, has introduced a new range of Thermo Scientific Verso™ cDNA synthesis kits and one-step reverse transcription - polymerase chain reaction (RT-PCR) kits. These kits combine a new reverse transcription enzyme, improved priming options and optimised buffers to generate high yield of full length cDNA. Designed to save time by minimising the steps involved in the RT-PCR protocol, the kits allow users to benefit from optimum flexibility and sensitivity in an easy to use format.

The new Verso RT Enzyme utilised in the kits has an improved dynamic range which maximises sensitivity and allows users to detect a wider range of starting template concentrations. The enzyme mix also includes an RNase inhibitor which significantly reduces RNase contamination whilst simplifying pre-RT setup steps.

Verso RT-PCR kits offer laboratories the flexibility of using anchored oligo dT or random hexamers in a reaction. The combination of these primers in the reverse transcription step gives greater coverage and yield of cDNA from RNA, resulting in greater reaction efficiency.

Several kit options are available in the Thermo Scientific Verso range to meet individual users’ specific needs. These include kits incorporating the ReddyMix™ buffer system which save time by allowing PCR products to be loaded directly onto an agarose gel. Kits are also available with Thermo-Start™ DNA polymerase in the master mix for maximum specificity in the PCR reaction.

The Verso RT Enzyme is also included in a new range of Thermo Scientific Verso QRT-PCR kits for QPCR users.polymerase in the master mix for maximum specificity in the PCR reaction.

The Verso RT Enzyme is also included in a new range of Thermo Scientific Verso QRT-PCR kits for QPCR users.

Full Story here.

Traditional approaches to large scale genotyping involve numerous microwell plates, large amounts of costly reagents and dispensing robotics to cope with the intensive liquid handling.

According to Mike Lucero, executive vice president of Sales and Marketing at Fluidigm, the IFCs are three dimensional microfluidic devices that have 48 reagent ports and 48 reaction ports that allow 2,304 parallel nano-volume reactions in each IFC.

This is achieved by driving a precise amount of reagents and reactants into chambers in the IFC that are limited by valves.

"Microfluidics got the reputation for not being able to find the appropriate application - but its inside out because in the past microfluidics didn't have the valves so they couldn't achieve the integration and miniaturisation that we have now - it's the valves that make the difference," said Lucero

Full Story here.